Tumour-associated directed immunity in prostatic cancer: Effect of amygdalin

R. A. Bhatti, R. J. Ablin, P. D. Guinan

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The effect of the in vivo treatment of peripheral blood leukocytes (PBL) from patients with prostatic cancer with the controversial drug amygdalin (AMG), commonly mislabeled as laetrile, on tumour-associated immunity (TAI) was evaluated by leukocyte adherence inhibition, a suggested in vitro correlate of cellular immunity. A significant (P <0.001) increase in reactivity to malignant prostate was observed with AMG treated PBL from 78% of the patients evaluated. The observed increase in TAI in the presence of AMG may be due to an immunopotentiating effect of this drug. Whether the observed in vitro increase in TAI reflects a similar increase in tumor-host responsiveness in vivo remains to be demonstrated.

Original languageEnglish (US)
Pages (from-to)19
Number of pages1
JournalIRCS Medical Science
Issue number1
StatePublished - 1981
Externally publishedYes

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Tumour-associated directed immunity in prostatic cancer: Effect of amygdalin'. Together they form a unique fingerprint.

Cite this